Amicus (FOLD) Gets a Hold from Morgan Stanley

Morgan Stanley analyst Andrew Galler maintained a Hold rating on Amicus (FOLDResearch Report) today and set a price target of $15.00. The company’s shares opened today at $10.41.

According to TipRanks, Galler is a 3-star analyst with an average return of 4.2% and a 60.00% success rate. Galler covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Amicus, and PTC Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amicus with a $14.33 average price target, a 37.66% upside from current levels. In a report released today, Berenberg Bank also maintained a Hold rating on the stock with a $12.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Amicus’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $80.73 million and a GAAP net loss of $62.16 million. In comparison, last year the company earned a revenue of $77.41 million and had a GAAP net loss of $51.23 million

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FOLD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Read More on FOLD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More